Congenital Insensitivity to Pain

Abstract

Congenital insensitivity to pain (CIP) is a group of rare inherited disorders in which a person cannot feel physical pain from birth, despite otherwise normal intelligence and largely intact touch, temperature, and proprioception. It is not stoicism or a raised pain threshold but a genuine absence: the machinery that detects and signals tissue damage is broken at a specific molecular step, most famously a loss-of-function mutation in SCN9A, which encodes the sodium channel Na_v1.7 that pain-sensing neurons need to fire. Because pain is protective, its absence is dangerous rather than pleasant, producing repeated unnoticed injuries, burns, and joint destruction. For cognitive psychology the condition is a natural experiment of unusual clarity: it dissociates the detection of a noxious stimulus from the felt experience of pain, showing that pain is a perceptual construction rather than a direct readout of bodily harm.

Keywords: congenital insensitivity to pain, nociception, SCN9A, Na_v1.7, hereditary sensory and autonomic neuropathy

Pain is so reliably unpleasant that its absence sounds like a gift, and this is the first thing about CIP that everyday intuition gets wrong. A child who cannot feel pain bites through the tongue, chews the fingers, walks on a fractured leg, and scalds the skin without complaint, because the signal that would normally command care and withdrawal never arrives (Nagasako, Oaklander, & Dworkin, 2003). Pain, in other words, is not the injury; it is the nervous system's alarm about the injury, and CIP is what a life looks like when the alarm was never wired.

That dissociation is exactly what makes the condition valuable beyond the clinic. The stimuli that ought to hurt still reach the body, and the tissue is still damaged, yet nothing is felt. The account below moves from what CIP is, through the kinds clinicians distinguish and the molecular faults that cause them, to what the condition reveals about pain as a constructed perception, and finally to how it is diagnosed and where its study is heading. The recurring theme is that pain is built, not received — and that a single missing channel can prevent the building.

Figure 1

Where the Pain Signal Is Blocked in SCN9A-Related CIP

What Congenital Insensitivity to Pain Is

Congenital insensitivity to pain is the inability, present from birth, to perceive physical pain, in a person whose other faculties are intact. The defining feature is a selective loss: sharp, burning, and aching pain are absent, while in the purest forms the ability to feel light touch, vibration, warmth, cold, and the position of the limbs is preserved (Cox et al., 2006). This selectivity is what marks CIP off from a general numbness or a nerve injury that abolishes all sensation; the person feels the pinprick as a touch and the flame as heat, but neither as something that hurts.

The condition is emphatically not a psychological one. It is not endurance, not indifference cultivated through training, and not a merely elevated threshold that a strong enough stimulus would overcome. The fault is in the biology of the nervous system, and it is complete: no stimulus, however extreme, produces pain, because the signal never reaches the point where pain would be constructed (Nagasako et al., 2003). This is why the disorder is diagnosed not by asking whether pain is felt but by tracing the molecular and neuronal reason it cannot be.

Precisely because pain is protective, its absence is a serious medical problem rather than a relief. Pain is the body's instruction to stop, withdraw, guard, and heal; a person who cannot feel it accumulates injuries that others avoid reflexively — oral self-mutilation from biting, corneal damage, painless fractures, burns, and a progressive destruction of weight-bearing joints known as Charcot arthropathy (Nagasako et al., 2003). Life expectancy and quality of life in CIP are limited chiefly by these unguarded injuries, which is the clearest possible demonstration of what pain is for.

Kinds of Congenital Painlessness

Congenital painlessness is not a single disease but a family of disorders, distinguished by whether the pain neurons are absent or merely silenced, by what else is lost alongside pain, and by which gene is at fault. The traditional clinical framework places several of them among the hereditary sensory and autonomic neuropathies (HSANs), a set of inherited conditions affecting the sensory and autonomic nerves, within which the pain-insensitivity syndromes form a recognisable cluster (Rotthier, Baets, Timmerman, & Janssens, 2012).

The most important division is between two mechanisms. In channelopathy CIP the pain neurons are present and structurally normal but cannot fire, because a channel they depend on is missing; this is the SCN9A form, in which touch and other sensations are typically spared and the loss is close to purely of pain (Cox et al., 2006). In neurodevelopmental CIP the pain neurons themselves fail to survive or develop, so the deficit is structural; the archetype is congenital insensitivity to pain with anhidrosis (CIPA, also called HSAN type IV), caused by mutations in NTRK1, in which the same nerve-growth-factor signal that pain neurons need is also required by the nerves that drive sweating, so an inability to sweat accompanies the insensitivity (Indo et al., 1996).

Two cautions keep this taxonomy honest. First, the categories describe mechanism and associated features, not severity alone: two children with painlessness may share almost nothing at the genetic level, and the accompanying signs — sweating, smell, tearing, intellect — are often what point to the responsible gene (Nahorski, Chen, & Woods, 2015). Second, the list keeps growing: rarer causes such as ZFHX2 have been added as individual families are sequenced, so congenital painlessness is best thought of as a converging phenotype reached by many genetic routes rather than one disease (Habib et al., 2018).

The Molecular Basis

The turning point in understanding CIP came in 2006, when a study of consanguineous families in northern Pakistan — including a child performer who placed knives through his arms and walked on burning coals without pain — traced their complete insensitivity to loss-of-function mutations in SCN9A (Cox et al., 2006). SCN9A encodes Na_v1.7, a voltage-gated sodium channel concentrated in the peripheral pain-sensing neurons. Na_v1.7 acts as a threshold amplifier: it boosts small depolarisations toward the point at which a full impulse fires, so without it the nociceptor detects a noxious stimulus but cannot convert that detection into a propagating signal. The result is a neuron that is alive, connected, and specifically deaf to pain. The finding generalised quickly: loss-of-function SCN9A mutations were soon confirmed as the cause of congenital pain insensitivity in several unrelated populations, establishing the channel rather than any one family as the locus of the defect (Goldberg et al., 2007).

The same channel tells a symmetrical story from the other direction. Gain-of-function mutations in the very same SCN9A gene make Na_v1.7 fire too easily, producing inherited disorders of excess pain such as inherited erythromelalgia and paroxysmal extreme pain disorder — so a single gene spans the full range from no pain to relentless pain depending on whether the channel is turned down or up (Drenth & Waxman, 2007). This bidirectional control is why Na_v1.7 became one of the most intensively studied targets in the search for new analgesics (Dib-Hajj et al., 2013).

Other genes reach painlessness by removing not the channel but the neuron. The nerve growth factor pathway — the growth factor NGF and its receptor TrkA, encoded by NTRK1 — is required for pain neurons to survive during development; mutations in NTRK1 cause CIPA by letting those neurons die, and mutations in NGF itself cause a related loss of pain (Indo et al., 1996; Einarsdottir et al., 2004). Later work identified the transcriptional regulator PRDM12, needed for pain neurons to develop at all, as another cause (Chen et al., 2015), and rarer routes continue to emerge, including a point mutation in ZFHX2 and a microdeletion affecting the FAAH pathway that together show how many distinct molecular steps the experience of pain depends on (Habib et al., 2018; Habib et al., 2019).

Pain as Perception

The deepest lesson of CIP is conceptual, and it turns on a distinction that ordinary language blurs. Nociception is the detection of actual or threatened tissue damage by specialised receptors and the transmission of that information toward the brain; pain is the conscious, unpleasant experience that the brain may or may not construct from it. In everyday life the two travel together so reliably that they seem identical, and it is tempting to think that pain simply is the arrival of a damage signal. CIP breaks them apart cleanly (Dib-Hajj et al., 2013).

In SCN9A-related CIP the receptors that begin nociception are present and the tissue damage is real, but the signal cannot propagate, so no pain is built — nociception is attempted and pain never occurs. The condition therefore functions as a natural dissociation of the kind cognitive psychology prizes: it isolates one component of a normally unified process and shows that the felt experience is not the stimulus but a construction the nervous system performs upon it, a construction that can fail at a definable step while everything upstream and much downstream remains intact (Cox et al., 2006). Pain, on this evidence, belongs with the other perceptions — assembled, not received.

That framing is reinforced by what happens when Na_v1.7 is missing in a slightly different way. People and mice lacking the channel are insensitive to pain not only because impulse transmission fails but because the loss triggers a compensating rise in the body's own opioids; blocking those opioids can partly restore pain sensitivity, showing that the painless state is an actively maintained construction with more than one contributing mechanism, not a simple broken wire (Minett et al., 2015). The absence of pain, like its presence, is something the nervous system produces.

Diagnosis and Assessment

CIP is usually first suspected in infancy or early childhood, not from a complaint of no pain but from its consequences: a baby who does not cry when injured, self-inflicted wounds to the tongue and fingers as teeth erupt, corneal scratches, and fractures or burns that went unnoticed (Nagasako et al., 2003). Because the child cannot report the absent symptom, the diagnosis rests on the pattern of unguarded injury together with a careful demonstration that pain sensation is missing while other modalities are preserved.

Assessment proceeds by mapping which sensations remain. Clinical sensory testing checks whether touch, vibration, warmth, cold, and joint position are intact against the specific absence of pain, and the associated features are decisive for pointing to a cause: the presence or absence of sweating, of the sense of smell, of tearing, and of intellectual disability each narrows the genetic possibilities before any gene is examined (Nahorski et al., 2015). A history of consanguinity raises the prior probability, because most CIP is inherited in an autosomal recessive pattern.

Confirmation is genetic. Sequencing the candidate genes — SCN9A, NTRK1, NGF, PRDM12, and the rarer causes — identifies the responsible mutation, distinguishing the channelopathy forms from the neurodevelopmental ones and giving a firm basis for genetic counselling of the family (Bennett & Woods, 2014). Management is entirely protective rather than curative: because the missing alarm cannot yet be restored, care consists of preventing and promptly treating the injuries the person cannot feel — dental guards, eye protection, foot and joint surveillance, and vigilant attention to temperature and trauma.

Worked Example

Because most CIP is autosomal recessive, its frequency in a population follows directly from the frequency of the faulty allele, and the arithmetic shows why the condition is so strongly associated with consanguineous families. Suppose a loss-of-function SCN9A allele has a frequency of q = 0.01 in some population — one copy in every hundred. The Hardy–Weinberg relation then fixes how the three genotypes are distributed at birth.

The frequency of unaffected carriers, who have one faulty and one working copy, is 2pq, where p = 1 − q = 0.99:

carriers = 2 × 0.99 × 0.01 = 0.0198 ≈ 1 in 51

The frequency of affected individuals, who carry two faulty copies, is q²:

affected = 0.01² = 0.0001 = 1 in 10,000

So carriers outnumber affected individuals by about two hundred to one — the recessive allele is overwhelmingly hidden in healthy carriers, which is why CIP can appear in a family with no previous history. Now introduce consanguinity. For the child of first cousins the coefficient of inbreeding is F = 1/16 = 0.0625, and the probability of a recessive condition rises to q²(1 − F) + qF, which rearranges to q² + Fq(1 − q):

affected = 0.0001 + 0.0625 × 0.01 × 0.99 = 0.0001 + 0.00061875 ≈ 0.00072

That is about 1 in 1,391, roughly a sevenfold increase over the 1 in 10,000 of the general population (0.00072 ÷ 0.0001 ≈ 7.2). The example makes concrete why the pivotal SCN9A families were consanguineous (Cox et al., 2006): inbreeding does not change the allele frequency, but it sharply raises the chance that a carrier's two copies meet in one child, converting a rare hidden allele into a visible disorder. The demonstration below lets these frequencies be varied and shows the resulting genotype distribution.

Discussion

CIP has earned a place in cognitive psychology well beyond its rarity, because it makes visible a principle that ordinary, pain-accompanied injury hides: the hurt is not the harm. When the machinery of nociception is broken at one identified step, tissue damage proceeds exactly as before but the experience of pain does not occur, which is the strongest available evidence that pain is a perception the nervous system constructs rather than a direct sensory readout of injury (Cox et al., 2006; Dib-Hajj et al., 2013). What the condition removes is not the damage but the alarm, and the two turn out to be separable.

The single-gene clarity of the disorder is what gives it its force. Because a loss-of-function change in SCN9A abolishes pain while sparing other sensation, and a gain-of-function change in the same gene produces pain in excess, the felt intensity of pain can be tuned up and down by the state of one channel (Drenth & Waxman, 2007). Few phenomena in perception allow a subjective experience to be mapped so precisely onto a single molecular variable, and fewer still let that variable be pushed in both directions.

For theory, the enduring point is that pain is a constructed, defensible state the nervous system maintains, not a passive signal it relays. It can be abolished by a missing channel; it can be actively held down by compensating opioid mechanisms when that channel is gone (Minett et al., 2015); it can be exaggerated when the channel is overactive; and its normal role is to command protective behaviour, which is why its absence is dangerous rather than desirable. Studying how the construction fails in CIP is one of the most direct routes into how normal pain — and, by extension, perception more generally — is assembled.

Current Directions

The most active front is therapeutic, and it runs in the opposite direction to the disorder. If losing Na_v1.7 abolishes pain without abolishing other sensation, then a drug that selectively blocks Na_v1.7 might relieve pain with few side effects — a rationale that has made the channel one of the most pursued analgesic targets of the past two decades (Emery, Luiz, & Wood, 2016). Progress has been harder than the genetics promised, in part because the discovery that endogenous opioids contribute to the painless state implies that simply blocking the channel may not reproduce the full analgesia seen in people who lack it from birth (Minett et al., 2015).

A second direction turns the rare newer genes into leads. The finding that a microdeletion affecting the FAAH pathway raises the body's own cannabinoid-like molecules and produces pain insensitivity has opened a distinct pharmacological avenue, and studies of how Na_v1.7 loss reshapes human nociceptor function are clarifying why some channel blockers have disappointed in trials while pointing to what a successful one would need to do (Habib et al., 2019; McDermott et al., 2019). Each newly sequenced painless family adds another molecular step whose manipulation might, in principle, relieve pain in people who have too much of it.

Common Misconceptions

“People with CIP feel no sensation at all.”

In the purest forms the loss is specific to pain. Touch, vibration, warmth, cold, and limb position are typically preserved, so a person feels a pinprick as a touch and a flame as heat — just not as pain (Cox et al., 2006).

“Not feeling pain would be an advantage.”

The opposite is true. Pain is protective, so its absence leads to unnoticed burns, fractures, oral self-mutilation, and progressive joint destruction; life is shortened and endangered by injuries that pain would have prevented (Nagasako et al., 2003).

“CIP is a matter of willpower or a very high pain threshold.”

It is neither. The insensitivity is complete and biological: no stimulus, however extreme, produces pain, because a specific molecular step in the pain pathway is missing from birth (Nagasako et al., 2003).

“There is a drug that cures CIP.”

There is not. Management is protective — preventing and treating the injuries the person cannot feel — while research on the same channels aims instead at new painkillers for people with excess pain (Emery et al., 2016).

Commonly Confused With

CIP vs. Pain Asymbolia

Both involve a disconnection between injury and suffering, but at different points in the pathway. In congenital insensitivity to pain the nociceptive signal never reaches the brain, so there is no pain sensation to react to. In pain asymbolia the signal arrives and the sensation is felt — the person can locate and describe the pain — but its normal unpleasantness and the urge to withdraw are absent, so pain is perceived without being minded. Ask whether the pain is not felt (CIP) or felt but not cared about (pain asymbolia); the first is a failure of transmission, the second a failure of the affective response the brain attaches to a signal it did receive.

Glossary

Anhidrosis.

The inability to sweat, present in CIPA because the nerve-growth-factor signal that pain neurons need is also required by the nerves that control sweating.

Autosomal recessive.

An inheritance pattern in which a disorder appears only when both copies of a gene are faulty, so unaffected carriers can transmit it and consanguinity raises the risk.

Channelopathy.

A disorder caused by faulty ion channels; in SCN9A CIP the pain neurons are intact but cannot fire because the Na_v1.7 channel is missing.

Charcot arthropathy.

Progressive destruction of a weight-bearing joint that results from the loss of the protective pain that would normally limit its use.

CIPA.

Congenital insensitivity to pain with anhidrosis (HSAN type IV); caused by NTRK1 mutations, adding an inability to sweat to the loss of pain.

Coefficient of inbreeding (F).

The probability that the two copies of a gene in an individual are identical by descent from a common ancestor; 1/16 for the child of first cousins.

Hardy–Weinberg relation.

The rule linking allele frequencies to genotype frequencies in a large randomly mating population, giving affected frequency q² for a recessive allele of frequency q.

Hereditary sensory and autonomic neuropathy (HSAN).

A family of inherited disorders of the sensory and autonomic nerves, within which several congenital pain-insensitivity syndromes are classified.

Na_v1.7.

A voltage-gated sodium channel, encoded by SCN9A and concentrated in pain neurons, that amplifies small depolarisations toward the threshold for firing an impulse.

Nerve growth factor (NGF).

A signalling protein, acting through the TrkA receptor encoded by NTRK1, that pain neurons require to survive and develop.

Nociception.

The detection of actual or threatened tissue damage by specialised receptors and its transmission toward the brain; distinct from the felt experience of pain.

Nociceptor.

A sensory neuron specialised to detect noxious — potentially damaging — stimuli such as extreme heat, pressure, or chemical injury.

Pain.

The conscious, unpleasant experience the brain constructs from nociceptive input; it may fail to occur even when nociception is attempted, as in CIP.

SCN9A.

The gene encoding Na_v1.7; loss-of-function mutations cause congenital insensitivity to pain, gain-of-function mutations cause inherited pain disorders.

Key Researchers

David L. H. Bennett

(living). Clinical neuroscientist at the University of Oxford whose work on painful and painless channelopathies helped frame the spectrum from too little to too much pain, and who defined the functional role of Na_v1.7 in human nociception (Bennett & Woods, 2014; McDermott et al., 2019). Faculty page

James J. Cox

(living). Human pain geneticist at University College London and first author of the study that identified SCN9A loss of function as a cause of the inability to feel pain, and later of the ZFHX2 and FAAH-pathway discoveries (Cox et al., 2006; Habib et al., 2018). Faculty page

Yasuhiro Indo

(living). Paediatrician and geneticist at Kumamoto University who discovered that mutations in NTRK1, the nerve-growth-factor receptor gene, cause congenital insensitivity to pain with anhidrosis (Indo et al., 1996). Faculty page

Stephen G. Waxman

(living). Neurologist at Yale University whose work on the Na_v1.7 sodium channel mapped the spectrum of human pain disorders it produces, from insensitivity to inherited excess pain (Drenth & Waxman, 2007; Dib-Hajj et al., 2013). ORCID

John N. Wood

(living). Neurobiologist at University College London who heads the Molecular Nociception Group and showed that endogenous opioids contribute to the painlessness of Na_v1.7 loss, reframing the channel as an analgesic target (Minett et al., 2015; Emery, Luiz, & Wood, 2016). ORCID

C. Geoffrey Woods

(living). Clinical geneticist at the University of Cambridge and senior author of the SCN9A discovery, whose subsequent reviews of the new Mendelian disorders of painlessness charted the widening genetic map of the condition (Cox et al., 2006; Nahorski, Chen, & Woods, 2015). Faculty page

Frequently Asked Questions

What is congenital insensitivity to pain?

It is a group of rare inherited disorders in which a person cannot feel physical pain from birth, despite normal intelligence and, in the purest forms, largely normal touch, temperature, and body-position sense. The fault lies in the neurons that detect and transmit tissue damage, not in a person's attitude to pain.

Is congenital insensitivity to pain dangerous?

Yes, seriously so. Pain normally warns the body to stop and protect itself, so its absence leads to unnoticed burns, fractures, eye injuries, oral self-mutilation, and progressive joint destruction. Life expectancy and quality of life are limited chiefly by these unguarded injuries.

What causes congenital insensitivity to pain?

Most cases are caused by inherited mutations in single genes. The best-understood is a loss-of-function mutation in SCN9A, which removes the Na_v1.7 sodium channel that pain neurons need to fire. Other genes, such as NTRK1, NGF, and PRDM12, cause related conditions by preventing pain neurons from developing or surviving.

How is congenital insensitivity to pain different from not caring about pain?

In this condition the pain is never felt at all, because the signal does not reach the brain. In pain asymbolia, by contrast, pain is felt and can be described, but its unpleasantness and the urge to withdraw are missing. One is a failure to receive the signal, the other a failure to mind it.

Can people with congenital insensitivity to pain feel touch?

In the channelopathy form caused by SCN9A loss, yes. Touch, vibration, warmth, cold, and limb position are typically preserved, and only pain is absent. In forms where the pain neurons themselves die, such as CIPA, other functions like sweating are also affected.

Why is congenital insensitivity to pain more common in some families?

Because it is usually recessive, it appears only when a child inherits a faulty gene copy from both parents. Marriage between relatives raises the chance that both parents carry the same rare faulty copy, which is why many of the families in which the condition was discovered were consanguineous.

Does the study of this condition help people with ordinary pain?

Potentially, yes. Because losing the Na_v1.7 channel abolishes pain without abolishing other sensation, drugs that block that channel are being pursued as new painkillers. Newer genetic causes have opened further avenues, though turning the genetics into effective treatments has proved difficult.

Is there a cure for congenital insensitivity to pain?

No cure exists. Care is protective: preventing and promptly treating the injuries the person cannot feel, through measures such as dental guards, eye protection, and regular checks of the feet and joints. Genetic counselling helps affected families understand the risk to future children.

References